Monika Conchon
Overview
Explore the profile of Monika Conchon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
94
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pagnano K, Peralta E, Navarro J, David Salas L, Delgado N, Moiraghi B, et al.
Leuk Lymphoma
. 2021 Jul;
62(13):3212-3218.
PMID: 34254886
This observational, multicenter study aimed to report the clinical evolution of COVID-19 in patients with chronic myeloid leukemia in Latin America. A total of 92 patients presented with COVID-19 between...
2.
Seguro F, Silva C, Moura C, Conchon M, Fogliatto L, Funke V, et al.
Hematol Transfus Cell Ther
. 2020 Jul;
43(2):191-200.
PMID: 32631809
This manuscript summarizes the results of the consensus meeting composed of hematologists and cardiologists to establish recommendations for the prevention and follow-up of cardiovascular (CV) risk in patients with chronic...
3.
Tavares R, Nonino A, Pagnano K, Nascimento A, Conchon M, Fogliatto L, et al.
Hematol Transfus Cell Ther
. 2019 Jun;
41 Suppl 1:1-73.
PMID: 31248788
No abstract available.
4.
Pagnano K, Bendit I, Boquimpani C, de Souza C, Miranda E, Zalcberg I, et al.
Cancer Invest
. 2015 Aug;
33(9):451-8.
PMID: 26288116
This is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41%) patients, mutations were detected. The most frequent...
5.
Pagnano K, Bendit I, Boquimpani C, de Souza C, Miranda E, Zalcberg I, et al.
Cancer Invest
. 2015 Aug;
PMID: 26279306
This is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41%) patients, mutations were detected. The most frequent...
6.
7.
Conchon M, Freitas C, Rego M, Braga Junior J
Rev Bras Hematol Hemoter
. 2013 Jan;
33(2):131-9.
PMID: 23284261
Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the...
8.
de Souza C, Pagnano K, Bendit I, Conchon M, Freitas C, Coelho A, et al.
Rev Bras Hematol Hemoter
. 2012 Nov;
34(5):367-82.
PMID: 23125546
No abstract available.
9.
10.
Bendit I, Sanabani S, Conchon M, Serpa M, Novaes M, Nardinelli L, et al.
Acta Haematol
. 2012 Aug;
128(4):223-32.
PMID: 22922489
Here we compare the management and survival outcomes of chronic myeloid leukemia (CML) patients who had early or late imatinib mesylate (IM) therapy. The cytogenetic and molecular responses of 189...